METHAMIDOPHOS EXPLANATION Methamidophos was evaluated by the Joint Meeting in 1976, when an ADI was allocated (Annex 1, FAO/WHO, 1977a). A toxicological monograph was prepared (Annex 1, FAO/WHO, 1977b). Some relevant toxicological studies from Industrial Bio-test Laboratories (IBT), supporting the 1976 evaluation, have been found to be invalid. The compound was re-evaluated in 1982, when some substitute studies were made available (Annex 1, FAO/WHO, 1983a). A monograph addendum was prepared (Annex 1, FAO/WHO, 1983b). The 1982 JMPR allocated a temporary ADI and requested long-term studies, a carcinogenicity study, and a reproduction study. The required studies, along with other toxicological studies, have been submitted and are summarized in this monograph addendum. Those sections of the 1976 evaluation summarizing invalid IBT studies have been superseded by the 1982 and 1985 re-evaluations. EVALUATION FOR ACCEPTABLE DAILY INTAKE BIOLOGICAL DATA Biochemical aspects Absorption, distribution, excretion, and metabolism Rat Male and female albino rats were each given orally a single dose of 32p_ labelled methamidophos at a level of 15 mg/kg b.w. After 24 hours, 77% of the administered radioactive dose was recovered in the urine. Identified urinary metabolites were; phosphoric acid, S-methyl thiophosphoric acid, O,S-dimethyl thiophosphoric acid, O-methyl phosphoric acid amide, and S-methyl phosphoramidothioic acid. Unchanged methamidophos and a highly non-polar unidentified metabolite were detected in the urine (Fakhr et al., 1982). The tissue distribution and excretion of 14CH3S-methamidophos was followed in female Sprague-Dawley rats after i.v. injection at a toxic, but non-lethal, dose (8 mg/kg). Radiolabel was rapidly distributed to all tissues at approximately equal concentrations. Peak tissue levels were achieved within 1-10 minutes except in the central and peripheral nervous system, where peak levels (40 nmol/g) were found between 20 and 60 minutes, corresponding to peak signs of toxicity. Within 24 hours of dosing, 47% of the radioactivity was recovered in the urine and 34% as 14CO2, with < 5% in the faeces over 7 days (Gray et al., 1982). Effects on enzymes and other biochemical parameters Acetylcholinesterase (AChE) inhibition was measured in erythrocytes, plasma, and various regions of the central nervous system (CNS) at selected times after i.v. administration of methamidophos at 8 mg/kg to rats. The degree of Ache inhibition in 3 CNS regions was similar, reaching a minimum activity of 15-20% of control values at 30-60 minutes, when toxicity was most severe. The degree of erythrocyte AChE inhibition was less that that of the CNS, although the time course was similar. Plasma AChE inhibition was more rapid than that of the CNS or erythrocytes, and reactivation was slower. When similar concentrations of methamidophos to those found in vivo were incubated with CNS homogenates, plasma, or erythrocytes in vitro (3 × 10-3), a similar degree of inhibition occurred over the same time course. Therefore, the authors concluded that cholinergic toxicity produced by methamidophos is a result of the in vivo stability of this compound, which permits its entry into the nervous system in sufficiently-high concentrations to inhibit AChE (Gray et al., 1982). The methylthiophosphorous linkage of methamidophos is cleaved in the reaction, leading to the inhibition of acethylcholinesterase (Thompson & Fukuto, 1982). Special studies on embryotoxicity and teratogenicity Rat Groups of 22-26 pregnant female CD rats were administered once daily, by gavage, methamidophos (technical grade, 70.5% a.i.) at dose levels of 0, 0.3, 1.0, or 3.0 mg/kg b.w. on days 6 through 15 of gestation, inclusive. These dosages were based on preliminary work using dams dosed at 0.5, 1.5, or 4.5 mg/kg b.w. Dams in the 4.5 mg/kg b.w. group aborted their litters at approximately day 15 of gestation; dams treated at 1.5 mg/kg b.w. carried their litters to day 21. The positive control group received 350 mg/kg b.w. hydroxyurea on days 9, 10, and 11 of gestation. Body weights and feed consumption were measured on days 6, 13, and 21 of gestation. On day 21 of gestation, rats were sacrificed and Caesarean sections were performed. Foetuses were inspected grossly and were preserved for internal or skeletal examination. Signs of intoxication typical of cholinesterase-inhibiting compounds were observed only in the rats at 3.0 mg/kg b.w. on days 6-8 to day 20 of gestation. No mortality occurred in any of the groups. Body weights and feed consumption for rats at 3.0 mg/kg b.w. were significantly lower than those of the controls from days 13 to 21 of gestation; body-weight gain (absolute and corrected) was also significantly reduced. There were no statistically-significant differences between control and treated groups with respect to mean values per litter of implantations, early resorptions (no late resorptions occurred in any group), or live foetuses. The mean weights of live foetuses from dams at 3.0 mg/kg b.w. were significantly lower than those of the controls. There were no differences between control and treated groups with respect to the incidence of foetuses with gross internal or skeletal abnormalities. Increased incidences of abnormal foetuses were observed in the positive control group. The no-effect level for maternal and foetal toxicity was 1.0 mg/kg b.w.; that for embryotoxicity and teratogenicity was 3.0 mg/kg b.w. (Hixson, 1984a). Special studies on reproduction Groups of CD rats (26/sex/dietary level) were fed diets containing methamidophos (technical grade, 70.5% purity) at levels of 0, 3, 10, or 33 ppm. After at least 100 days of dosing, the F0 rats were mated to start a two-generation reproduction study with one set of F1 litters and 2 sets of F2 litters (F2a and F2b). Because mating was done on a 2-females-to-l-male basis, only half of the males in each group were used for mating. The remaining 13 males per group were continued on treated feed for possible use as replacement breeders. Necropsy was performed on F0 and F1 parents and F1a, F2a, and F2b weaned pups. Tissues processed for histopathology included reproductive organs from F0 males and females (when available), reproductive organs from F1 male and female adults, and gross lesions. The percent of F0 dams delivering was reduced in all treated groups, but not in a dose-related pattern. During gestation of F0 dams, feed consumption was comparable among groups, whereas body- weight gain of the 33-ppm dams was lower than in the controls. Although there was a trend toward decreased live births in F1 litters with increasing dose, the differences were not statistically significant. There was also a trend toward decreased viability compared with controls during the course of lactation; the difference was not statistically significant. For F1 pups in the 33-ppm dietary groups, mean pup weights from lactation day 4 onward and mean litter weights from lactation day 7 onward were significantly lower than in controls. Among F1 parents, rats in the 33-ppm dietary level had body weights significantly lower than controls throughout the growth period. The number of F1 dams delivering litters (as percent of sperm- positive females) were reduced in the 10-ppm and 33-ppm groups during production of F2a litters and in all treated groups during production of F2b litters; in both cases no clear dose-related pattern was evident. During gestation of F2a and F2b litters, body-weight gains of dams in the 33-ppm group were lower than in controls and in the other 2 treated groups, but not statistically-significantly different from controls. As with F1 litters, F2a and F2b litters showed a trend toward decreased live births, decreased lactation indices and decreased viability indices with increasing dose during lactation; however, the differences were statistically-significantly different from controls only on lactation day 14 for the mean number of pups per litter and the viability index of the 33-ppm F2a group and for the mean number of pups per litter of the 33-ppm F2b group. In the 33-ppm group, the F2a mean litter weight was significantly reduced compared to controls from day 1 onward, and the mean pup weight was significantly reduced throughout lactation. In the 33-ppm group, the F2b mean litter weight was significantly reduced compared to controls throughout lactation, but the mean pup weight was reduced only on lactation day 7. Sporadic differences from controls in absolute and relative gonad weights of adults and pups gave no evidence of a dose-related effect. Gross and microscopic changes were observed in control and test groups of each generation and were considered unrelated to treatment. Statistically-significant effects of methamidophos on reproduction occurred only at the 33-ppm dietary level; thus the no- effect level in this study was 10 ppm (Hixson, 1984b). Special studies on carcinogenicity Mouse Groups of CD1 albino mice (50 males and 50 females/sex/dietary level; 10 males and 10 females in the satellite groups) were fed diets containing methamidophos (70% purity) at levels of 0, 1, 5, or 25 ppm for 106 weeks. Mice in the satellite groups were used for haematology determinations at 6 months and 1 year. Ten mice were randomly selected among surviving mice for haematology at termination. All mice found dead or moribund-sacrificed during the study, interim sacrificed at 1 year, and terminal sacrificed were subjected to gross necropsy. The adrenals, brain with entire brainstem, gonads, heart, kidneys, liver, lungs, and spleen were weighed. A number of tissues and organs from all animals were subjected to histopathological examination. The administration of the test compound had no toxocological effect on behaviour, occurence of masses, or mortality. Feed consumption of the controls and those in the 1-ppm and 5-ppm groups were generally comparable. The 25-ppm females had a fairly consistent significant decrease in feed consumption after one year. Mean body weights of male and female mice in the 25-ppm group were significantly lower than controls in the second half of the study. Haematological values gave no indication of a treatment-related effect. Average absolute organ weights were generally comparable between the control and treated groups, except for lung weights of the 25-ppm female mice, which were higher than those of the controls, possibly due to the increased incidence of interstitial pneumonia present in that group. Relative average weights of adrenals, brain, heart, kidneys, and lungs of the 25-ppm females and of the brain of the 25-ppm males were significantly higher than those of the controls, possibly due to significantly-decreased body weights at the 25-ppm dietary level. Other than an increase in interstitial pneumonia in the 25-ppm females and males, the non-neoplastic histopathologic observations were those of spontaneous lesions of aging mice and were comparable between dietary levels. The neoplastic histopathologic observations were naturally- occurring neoplasms of aging mice. There were no unusual or rare tumours observed. On the basis of type, site, frequency distribution by sex, and dietary level, there was no indication of a dose-related effect. Moreover, there were no dose-related increases in animals with tumours (either single or multiple), with total tumours, with total benign tumours, with only single or multiple benign tumours, with at least one benign tumour, or with both benign and malignant tumours. There was an increase, interpreted as random, in total malignant tumours found in female mice fed 1 and 5 ppm, but not 25 ppm, methamidophos when compared to controls. There was also an increase in the number of animals with only malignant tumours in female mice fed 5 and 25 ppm methamidophos. These increases in malignant tumours were interpreted by the author as random, due to: 1) multiple tabulation of metastatic tumours and malignant lymphomas in 1 animal; 2) the lack of dose-relationship trends in animals with at least 1 malignant tumour and animals with both benign and malignant tumours; and 3) there was no dose-response relationship in the above-mentioned increases. In summary, there was no evidence of induced oncogenicity for mice consuming up to and including 25 ppm methamidophos in the diet for 106 weeks. The no-effect level in this study was 5-ppm, equal to 0.67 mg/kg b.w./day and 0.78 mg/kg b.w./day for males and females, respectively (Hayes, 1984a). Special studies on mutagenicity See Table 1. Acute toxicity See table 2. When administered to male rats, a combination of 53% cyfluthrin and 47% methamidophos had a lesser toxic effect (LD50 = 26.0 mg/kg b.w.) than expected (LD50=17.0 mg/kg b.w., assuming an additive effect) (Heinmann, 1983), Short-term studies Dog Groups of Beagle dogs (6/sex/dietary level) were fed diets containing methamidophos (70% purity) at levels of 0, 2, 8, or 32 ppm for 52 weeks. Table 1. Special studies on mutagenicity with methamidophos Test Test Range of doses Result Reference organism substance or concentration tested S. typhimurium Methamidophos 0.1-10.0 mg/ No significant Machadao TA1535, TA1537, technical plate differences of et al., TA1538, TA98, (% a.i. not revertants 1982 TAlO0 given) compared to negative control.* Mouse: Dominant lethal Methamidophos 0, 5, 50, 150 No significant Eisenlord, assay - 12 technical ppm (not differences et al., males/group; (74.3% a.i.) corrected for % indicative of a 1984 8 week mating a.i.), 5-day dominant lethal cycle, 2 females feeding effect between to 1 male control and treated groups. Mouse in vivo: Chromosomal Methamidophos 0.6, 2.0, 6.0, No significant Esber, 1983 aberrations technical 9.0, 12.0 mg/ differences in in bone marrow (74.4% a.i.) kg b.w. by chromosomal cells (4 M + gavage (as aberrations at 6, 4 F/dose level/ methamidophos) 24, or 48 hrs. test time) between control and treated groups. Table 1. (Con't) Test Test Range of doses Result Reference organism substance or concentration tested DNA damage: E. coli (K12) Methamidophos 0.625-10,000 No differences in Herbold, p3478, DNA (71.2% a.i.) µg/plate the zones of 1983 repair - (not corrected growth inhibition E. coli W3110 for % a.i.) indicative of DNA DNA repair + damage.* * Both with and without S-9 mix Table 2. Acute toxicity of methamidophos in the rat Test LD50* LC50* Sex comp. Route (mg/kg b.w.) (mg/m3) Reference M Methamidophos Oral 21.0 Duke et al., 1982 (73.1% a.i.) F Methamidophos Oral 16.2 Duke et al., 1982 (73.1% a.i.) M Methamidophos inhalation 377 Sangha, 1983 technical 1 hr. exp. (75.1% a.i.) F Methamidophos inhalation 241 Sangha, 1983 technical 1 hr. exp. (75.1% a.i.) M Methamidophos inhalation 63.2 Sangha, 1984 technical 4 hrs. exp. (70.5% a.i.) F Methamidophos inhalation 76.5 Sangha, 1984 technical 4 hrs. exp. (70.5% a.i.) * Not corrected for the % of a.i. Cholinesterase (ChE) activity of plasma and erythrocytes was determined on all dogs 3 times at weekly intervals prior to initiation of the study. After initiation, determinations were made twice monthly for 3 months, then every month and at termination of the study. Brain cholinesterase activity was determined at termination. Haematology, blood chemistry, and urinalysis were performed on all dogs prior to initiation, monthly for 3 months, then every other month and prior to termination of the study. Gross anatomical examination was performed on all the dogs sacrificed at termination. A number of tissues and organs from all animals were subjected to histopathological examination. No mortality occurred during the study. Daily observations for toxicological effects did not reveal treatment-related effects. The administration of the test compound did not affect feed comsumption or body weight. Plasma, erythrocyte, and brain cholinesterase activity of male and female dogs in the 2-ppm group were not significantly (< 20%) different from control values at each test period. At 8 and 32 ppm, a strong dose-related inhibition in cholinesterase activity, that remained constant throughout the study, was observed, except for the plasma cholinesterase in the 8-ppm females. Although statistically-significant differences in haematological, clinical chemistry, and urinalysis values between control and treated groups occurred sporadically, there was no evidence of treatment- or dose-related trends. Ophthalmological examination did not reveal any effect of treatment. Absolute and relative organ weights were not affected by the treatment. Gross necropsy and histopathological examination gave no indication of a treatment-related effect. The no-effect level in this study for ChE inhibition was 2 ppm, equal to 0.06 mg/kg b.w./day for both male and female dogs (Hayes, 1984b). Long-term studies Rat Groups of Fischer 344 rats (50/sex/dietary level, plus 10 reserve rats and 10 replacement rats/sex/dietary level) were fed diets containing methamidophos (70% purity) at levels of 0, 2, 6, 18, or 54 ppm for 2 years. Animals were observed for toxicological effects, abnormalities, masses (by palpation), and mortality. Feed consumption and body weights were determined weekly. Haematology and blood chemistry parameters (including cholinesterase) were determined at initiation, 6, 12, 18, and 24 months. Reserve rats were used for testing at 6 and 12 months, and 10 randomly-selected animals from the experimental groups were used for testing at 18 and 24 months. Also, plasma, erythrocyte, and brain cholinesterase inhibition were determined on control and 2-ppm replacement rats at 1 month. Due to a slight decrease in plasma cholinesterase activity at 12 months in 2-ppm female reserve rats, plasma and erythrocyte cholinesterase determinations were made on 10 male and 10 female rats from all dietary levels of chronic-study animals at 12 and 15 months. All moribund rats (which were sacrificed), all rats found dead during the study, and all rats interim-sacrificed at 1 year and at termination were subjected to gross necropsy. A number of tissues and organs from all animals were subjected to histopathological examination. The animals of the 2- and 6-ppm groups did not differ from the control animals in behaviour or appearance. Most animals of the 18- and 54-ppm groups showed, after about 20 weeks from the start of the study, loose stools, urine staining, rough coats, and skin lesions (predominantly tail rash) as the most frequently-seen signs. The number of masses, time of their first observation, and mortality were not affected by treatment. Mortality in all groups was in the range 2-6% and 18-30% at 78 and 105 weeks, respectively. Feed consumption at all dietary levels, including the controls, was erratic and no clear trend was apparent. Decreased body weights were observed in male rats at 18 and 54 ppm and in female rats at the 54-ppm dietary level. Although some statistically-significant differences occurred in haematology and blood chemistry values, there was no evidence of a dose-related effect. A strong, dose-related inhibition of plasma, erythrocyte, and brain cholinesterase activities was observed at each test period in the 6-, 18-, and 54-ppm groups, compared to the controls. The degree of inhibition was comparable for both sexes and remained almost constant throughout the study. The 2-ppm dietary level was the no- effect level for cholinesterase activity. Statistically-significant differences were observed in absolute and relative organ weights for males at 18 and 54 ppm and for females at 2, 6, 18, and 54 ppm, but they were within the normal range of untreated mature Fischer 344 rats (historical data for the laboratory were provided) and no dose-related effect was apparent. Gross and histopathological findings were comparable between control and treated groups. The type, site, time of onset, and incidence of neoplastic changes gave no indication of an oncogenic effect of methamidophos. The no-effect level in this study was 2 ppm, based on ChE inhibition (Hayes, 1984c). Observations in man "In workers engaged in the manufacture of methamidophos- formulated products an occasional temporary inhibition to a minor degree of cholinesterase activity was observed" (No determinations presented) (Kollert, 1981). There have been "no damaging effects on the well-being of the people engaged with the formulation of methamidophos" (Miksche, 1981). The clinical and electrophysiological findings in 10 patients (6 males aged 14-28 years), who developed polyneuropathy after exposure to the organo-phosphate (OP) insecticide "Tamaron(R)" (marketed in Sri Lanka) were analysed. The illness is characterized by 2 phases, an initial phase of cholinergic crisis, which responds to atropine or 2-PAM, and a delayed phase of paralysis of limbs, which develops 2-4 weeks after poisoning. Paralysis first affects the distal muscles of the lower limbs, and 2-4 days later the muscles of the hand and forearm are affected. On examination the affected muscles show weakness and wasting of varying severity. Four patients seen late in the course of the disease also had evidence of pyramidal-tract dysfunction. The late development of pyramidal-tract signs has also been reported in poisoning due to another OP compound, tricresyl phosphate. Electromyography of the distal limb muscles showed evidence of denervation to varying degrees. Motor nerve conduction was impaired in the distal segments of the nerves, while conduction in the proximal segments remained unaffected until the muscles were completely denervated. Senesory conduction was unaffected. An unusual feature of the polyneuropathy caused by Tamaron(R) was the asymmetry of neural involvement. In all patients, the right hand was affected more than the left hand, clinically as well as electrophysiologically. The observation that in all the cases the dominant limb was affected more severely raises the possibility that factors such as excessive use and fatigueability of muscles has a bearing on the pathogenesis of the neurophathy in OP poisoning (Senanayake, 1981; Senayake, 1984). Ten isolated cases of acute polyneuropathy seen over 3 years in Sri Lanka were reported. All 10 developed after poisoning by formulations of technical grade Tamaron(R), the main ingredient of which is methamidophos. A 22-year-old Sinhalese man was admitted to the hospital in an unconscious state, having ingested about 80 ml of 60% (w/v) Tamaron(R), in a suicide attempt, a few hours previously. The diagnosis of organophosphate poisoning was confirmed clinically by the presence of papillary constriction, muscular fasciculation, and profuse sweating. The patient was treated with atropine (270 mg in the first 24 hours), and with furosemide and penicillin. He remained unconscious for 24 hours, and then recovered gradually over the next 3 days. He was discharged 5 days after admission, with no symptoms except blurring of vision, which lasted for several days. Ten days after discharge he had pain with "pins and needles" in the feet, lasting for 3 days. This was followed by weakness of the feet and, a day later, by weakness of the hands. At the height of weakness, he had marked difficulty in walking and using his fingers. On examination, 1 month after the onset of weakness, he was unable to move his fingers against resistance and had bilateral footdrop, with marked weakness of the dorsiflexor muscles and the evertors of the feet. The muscle power of the knee flexors and the hip flexors was slightly impaired, but the tone of the proximal muscles was increased and of a spastic type. The tendon reflexes were exaggerated, except that the ankle jerks were absent. The plantar responses were flexor. Sensory testing, including 2-point discrimination, revealed no abnormalities. The results of the following investigations were within normal limits: erythrocyte sedimentation rate; haemoglobin and blood picture; white-cell count and differential-cell count; fasting blood sugar; liver-function test; urinalysis for albumin, porphobilinogen, and urinary sediment; and cerebrospinal-fluid test for sugar, proteins and cells. Electromyography of the distal muscles of the limbs showed changes due to denervation, but the motor-conduction velocity in the fastest-conducting fibers of the peripheral nerves supplying those muscles was relatively normal. During the 1-month stay in the hospital, with daily physiotherapy, the patient had a considerable improvement in muscle power. The clinical and laboratory findings in the other 9 cases were similar. Six had ingested the poison in an attempt at suicide. In the other 3, the exposure had been accidental; one had ingested the poison while attempting to aspirate the insecticide through a tube from the spraying machine, another had spilled the poison on his body while opening the bottle, and another had become intoxicated while spraying the insecticide. There was good evidence that each of the 10 patients had used Tamaron(R). The patients had an acute cholinergic crisis soon after exposure to the insecticide, with a polyneurophathy developing 2 to 3 weeks later. Six patients who were followed for 8 weeks or more also had evidence of pyramidal-tract involvement. Predominant motor paralysis affecting the distal muscles of the limbs, minimal sensory abnormalities, and calf pain preceding the onset of weakness are typical of polyneuropathy caused by organophosphate compounds, as are the electrophysiologic findings of partial denervation, with surviving fibres conducting at normal rates and the pyramidal-tract signs noted during the late stage of illness. All these features and the circumstantial evidence strongly suggest that the neurologic abnormalities in these patients were the result of delayed neurotoxicity caused by an organophosphate contained in the insecticide labeled "Tamaron(R)". Polyneuropathy in human beings had not been thought to be associated with this compound, as it has not produced neurologic damage in animals. It had been assumed that methamidophos is free of delayed neurotoxicity. However, the delayed neurotoxicity of some organophosphate compounds can only be demonstrated experimentally by using doses well above the short-term mean lethal dose, protecting the animal from the cholinergic crisis with atropine and oxime reactivators. The Tamaron(R) sold in Sri Lanka is formulated locally; it contains methamidophos as a 60% (w/v) solution in ethylene glycol monomethyl ether, with an added dispersing agent (5%). The trace of material remaining in the bottle from 1 of the above cases was identified as a typical formulation of Tamaron(R), which, besides methamidophos, normally contains small amounts of several related compounds as impurities (principally an isomer and the N-methyl analogue of methamidophos). Preliminary studies were performed on 2 samples of Tamaron(R) purchased in Sri Lanka, and compared with results with a purer sample of methamidophos (95% pure). The formulated material, which contained impurities similar to the ones in the sample analysed after poisoning, was much more potent in acute toxicity tests than an equivalent amount of methamidophos dissolved in water. However, the high potency did not appear to be due to any of the several impurities that have been identified. It is probably due to alterations in the pharmacokinetics of methamidophos caused by the solvent. The solvent may increase absorption or it may prolong the circulation life of the agent. When either pure or impure methamidophos was administered to hens at about twice the unprotected median-lethal dose, 50% inhibition of the target protein involved in initiation of neuropathy (commonly called neurotoxic esterase) was found. Thus, although no neuropathic response has ever been observed in hens given any formulation of methamidophos, the results of the target-protein assays deliver a clear warning (Senanayake & Johnson, 1982). COMMENTS Pharmacokinetic and metabolism studies indicate that methamidophos is rapidly absorbed, distributed, metabolized and excreted, mainly via urine as acid metabolites and through the expired air as CO2. In addition to the rabbit study evaluated in 1982, a no-effect level for embryotoxic/teratogenic effects was established in a rat study. A no-effect level was also found from data for reproductive effects. Methamidophos was found to be non-mutagenic in bacterial and in vivo assays. There were no indications of oncogenicity in a mouse oncogenicity study or in a rat chronic toxicity/oncogenicity study. A new 1-year dog study confirms the NOEL used for the derivation of the 1982 temporary ADI. Methamidophos caused delayed polyneuropathy in man following excessive exposure. However, maximum tolerated doses in hens failed to cause delayed neuropathy. The toxicology monograph prepared by the present meeting supersedes the monograph prepared in 1976. TOXICOLOGICAL EVALUATION LEVEL CAUSING NO TOXICOLOGICAL EFFECT Rat: 2 ppm in the diet, equal to 0.1 mg/kg b.w. Dog: 2 ppm in the diet, equal to 0.06 mg/kg b.w. ESTIMATE OF ACCEPTABLE DAILY INTAKE FOR MAN 0 - 0.0006 mg/kg b.w. FURTHER WORK OR INFORMATION DESIRED Observations in man REFERENCES Duke, C.E., Cisson, C.M., & Wong, Z.A. The efficacy of atropine (1982) sulfate and pralidoxime chloride (2-PAM) as antidotes for acute oral toxicity of Monitor(R) technical (SX-1244) in rats. Unpublished report No. SOCAL 1678 from Environmental Health and Toxicology, Chevron. Submitted to WHO by Bayer F.R.G. Eisenlord, G.H., Canver, J.H., & Wong, Z.A. Dominant lethal study of (1984) methamidophos technical in mice. Unpublished report No SOCAL 1783 from Environmental Health and Toxicology, Chevron. Submitted to WHO by Bayer F.R.G. Esber, H.J. In vivo cytogenetics study in mice - methamidophos (1983) technical (SX-1244). Unpublished report MRI-176-CCC-82-56 from EC&G/Mason Research Institute, Massachussets, USA. Submitted to WHO by Bayer F.R.G. Fakhr, I.M.I., Abdel-Hamid, F.M. & Afifi, L.M. In vivo metabolism of (1982) 32P-Tamaron(R) in the rat. Isotope Rad. Res, 14, 49-55. Gray, A.J., Thompson, C.M., & Fukuto, T.R. Distribution and excretion (1982) of (14CH3S)-methamidophos after intravenous administration of a toxic dose and the relationship with anticholinesterase activity. Pest. Biochem. Physiol., 18, 28-37. Hayes, R.H. Oncogenicity study of methamidophos technical (Monitor(R)) (1984a) in mice. Unpublished report No. 80-332-01 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Hayes, R.H. One-year feeding study of methamidophos (Monitor(R)) in (1984b) dogs. Unpublished report No. 81-174-01 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Hayes, R.H. Chronic feeding/oncogenicity study of methamidophos (1984c) (Monitor(R)) to rats. Unpublished report No. 81-271-01 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Heimann, K.G. FCR 1272 & SRA 5172 (c.n. cyfluthrin (proposed) and (1983) methamidophos)/study for combination toxicity. Unpublished report No. 12003 from Institute of Toxicology, Bayer AG. Submitted to WHO by Bayer F.R.G. Herbold, B. SRA 5172 (methamidophos)/pol test on E. coli to evaluate (1983) for DNA damage. Unpublished report No. 12318 from Institute of Toxicology, Bayer AG. Submitted to WHO by Bayer F.R.G. Hixon, E.J. Embryotoxic and teratogenic effects of methamidophos (1984a) (Monitor(R)) in rats. Unpublished report No. 82-611-01 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Hixon, E.J. Effects of methamidophos (Monitor(R)) on reproduction in (1984b) rats. Unpublished report No. 82-671-01 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Kollert, W. BBA - requirement/effects on humans. Unpublished internal (1981) letter, June 5, from Medical Department, Bayer AG. Submitted to WHO by Bayer F.R.G. Machadao, M.L., Parker, J.A., & Wong, Z.A. Salmonella/mammalian (1982) microsome mutagenicity test (Ames test) with Monitor(R) technical. Unpublished report SOCAL 1711 from Environmental Health & Toxicology, Chevron. Submitted to WHO by Bayer F.R.G. Miksche, L. Effect on humans/internal experiences. Unpublished (1981) internal letter, June 12, from Medical Department, Bayer AG. Submitted to WHO by Bayer F.R.G. Sangha, G.K. Acute inhalation toxicity study with technical (1983) methamidophos (Monitor(R)) in rats. Unpublished report No. 80-041-12 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Sangha, G.K. Acute inhalation toxicity study with technical (1984) methamidophos (Monitor(R)) in rats. Unpublished report No. 80-041-02 from Environmental Health Research, Mobay Chemical Corporation. Submitted to WHO by Bayer F.R.G. Senanayake, N. Clinical and electrophysiological features of (1981) polyneuropathy produced by a new organophosphate compound. Proc. Sri Lanka Assoc. Advance. Sci., 37, 5-6. Senanayake, N. Pesticide induced neuropathy in Sri Lanka: A clinical (1984) epidemiological and electrophysiological study. Proc. Sri Lanka Assoc. Advance. Sci., 40, 16-17. Senanayake, N. & Johnson, M.K. Acute polyneuropathy after poisoning by (1982) a new organophosphate insecticide. New Engl. J. Med., 306, 115-157. Thompson, C.M. & Fukuto, T.R. Mechanism of cholinesterase inhibition (1982) by Methamidophos. J. Agr. Food Chem., 30, 282-284.
See Also: Toxicological Abbreviations Methamidophos (HSG 79, 1993) Methamidophos (ICSC) Methamidophos (JMPR Evaluations 2002 Part II Toxicological) Methamidophos (Pesticide residues in food: 1976 evaluations) Methamidophos (Pesticide residues in food: 1979 evaluations) Methamidophos (Pesticide residues in food: 1981 evaluations) Methamidophos (Pesticide residues in food: 1982 evaluations) Methamidophos (Pesticide residues in food: 1984 evaluations) Methamidophos (Pesticide residues in food: 1990 evaluations Toxicology)